Stent firm talking up endoscopy business
685438
Plagued by chronic bad news about its marquee cardiovascular products, Boston Scientific Corp. yesterday moved to shift Wall Street's focus to a strong, solidly growing part of its business: Endoscopy products used in treating everything from kidney stones to throat and digestive-tract cancers.
455985
Should investors jump in or wait a bit on this maker of a robotic catheter system?
482556
Boston Scientific announces an investment in Â and strategic partnership with Â REVA Medical, which is working on a polymer successor to todayÂs metal stents that would be biodegradable in the body.
752070
Keep an eye on this small-cap industrial equipment firm.
614727
The FDA is about to make it harder for drug-eluting stents to win its approval.
452030
Advanced Medical Optics Inc., a maker of eye-care and surgical products, bid $75 a share for rival Bausch &amp; Lomb Inc., topping an offer from private-equity firm Warburg Pincus LLC, a person familiar with the matter said.
717588
Indianapolis-based Guidant Corp., which co-promotes Johnson &amp; Johnson&#39;s Cypher drug-coated heart stent, says the device&#39;s market share has risen by as much as half, helped by Boston Scientific Corp.
539969
Meta-analysis finds J&J's stents are safer than Boston Scientific's stents -- maybe.
593860
The company deserves the attention of those looking for a value play.
430085
Boston Scientific Corp. said yesterday it bought a stake in a San Diego maker of vascular stents made from plastic that biodegrades within patients' bodies, a potentially major advance.
173143
Johnson &amp; Johnson's drug-coated Cypher heart stent may be better than Boston Scientific's Taxus for repeat procedures to unclog some arteries, according to a study in the Jan. 12 Journal of the American Medical Association.
701196
Abbott Laboratories Inc.  on Friday said it submitted its application to the U.S. Food and Drug Administration for its drug-coated stent called Xience and expects to start selling the heart device in the first half of 2008.
105165
Advisers to the U.S. Food and Drug Administration on Friday will consider the risks of drug-coated stents in patients with medical complications who are not approved for the artery-opening heart devices.
646222
The anticipated merger of Guidant Corp. and Johnson &amp; Johnson could give an unintended boost to Boston Scientific Corp. if Guidant's drug-coated stent launch is delayed, said analysts looking at the implications of a potential deal.
93936
The concerns that have been raised about the safety of drug-eluting stents at a major cardiology conference shouldn't mean it's time to go back to older treatments, the chief medical and scientific officer of Natick medical technology company Boston Scientific Corp. said yesterday.
260929
The med-tech firm impresses on many levels.
40445
Boston Scientific announced an investment in Â and strategic partnership with Â REVA Medical, which is working on a polymer successor to todayÂs metal stents that would be biodegradable in the body.